This site is intended for Healthcare Professionals only

POM-GSL switch for esomeprazole

Conditions bookmark icon off

POM-GSL switch for esomeprazole

The Medicines and Healthcare products Regulatory Agency (MHRA) has reclassified the proton pump inhibitor (PPI) esomeprazole (Nexium Control) from a POM to a GSL medicine, making it available via pharmacies and supermarkets without a prescription

Pfizer acquired the rights to market non-prescription Nexium Control from AstraZeneca and hopes that the reclassification will offer an alternative option to antacids and alginates for the estimated eight million plus UK adults who frequently suffer from heartburn. PPIs work by blocking acid production in the stomach and are recommended by NICE as a first-line treatment for heartburn. However, they can increase the risk of fractures and GI infections if taken long-term. Nexium Control is indicated for the short-term management of heartburn and acid reflux in adults aged 18 and over and should not be taken for longer than 14 consecutive days.

Commenting on the switch, Kirit Patel, chief executive of Day Lewis Pharmacy, said: “The reclassification of Nexium as an OTC treatment is good news as it provides customers with access to another effective heartburn medication.” However, in response to a consultation on the reclassification held last summer, the Royal Pharmaceutical Society (RPS) expressed concerns that patients may fail to read the patient information leaflet with a GSL medicine and not realise that esomeprazole can only be used for up to two weeks. The RPS said: “Pharmacy sale of medicines is usually the first step in widening public access and offers added safety.” The launch of Nexium Control is being supported by ongoing pharmacy training and POS material in addition to a consumer advertising campaign.

Copy Link copy link button

Conditions

Share: